Bormioli Pharma has a complementary portfolio of pharmaceutical number-one packaging fabricated from glass and plastic, as well as closure solutions, add-ons, and dispensing systems. With this acquisition, Gerresheimer strengthens its European footprint with additional production websites, in particular in Southern Europe. The transaction is a challenge to commonplace ultimate conditions and approvals. Closing is expected within the fourth quarter of the 2024 monetary year.
“With this transaction, we’re putting an exclamation mark on our boom ambitions,” says Dietmar Siemssen, CEO of Gerresheimer. “Bormioli Pharma is an ideal strategic suit for us and speeds up our transformation into an included systems and solutions company. In unique, we’re expanding our portfolio to encompass in addition excessive-value answers. Both agencies supplement each other in terms of product portfolio and nearby coverage with production websites in Europe.”
“Bormioli Pharma has been a Triton portfolio organisation in view that 2017. Since our founding, the organization has long passed through a substantial transformation in recent years with double-digit worthwhile growth,” says Moritz Gudenus, funding advisory expert at Triton. “We are very pleased that we have observed an incredible accomplice for the corporation in Gerresheimer, who will preserve this achievement tale.”
Andrea Lodetti, CEO of Bormioli Pharma Group, stated: “With the help of Triton, we were capable of constructing out our positions throughout pharma packaging, with one-stop-store skills in terms of era in addition to product imparting. We thank the Triton group for their guide and stay up for our next chapter of the boom with Gerresheimer.”
